Halozyme Therapeutics shares are drawing renewed attention as analysts revise their outlooks, reflected in a slight decrease in the stock's Fair Value Estimate from $75.44 to $74.44. This adjustment comes as a result of a lowered revenue growth assumption, now at 16.2%, down from 19.1%, while consensus softens on the company's medium-term sales trajectory. Stay tuned to discover the latest factors shaping the narrative and how investors can keep track of these evolving developments.

Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value Halozyme Therapeutics.

???? Bullish Takeaways

Citizens JMP raised its price target on Halozyme to $92, highlighting the company's strong quarterly performance, particularly the indication and global expansion of ENHANZE partnered products. The firm expects Halozyme to achieve over $1 billion in EBITDA by 2026. This milestone is projected to be reached a year ahead of previous guidance.

Benchmark increased its price target to $90 from $75, maintaining a Buy rating. The firm cites anticipated growth amid the pending launch of a competing product and upcoming resolution of patent litigation. It also notes the company's continued execution and market positioning.

Morgan Stanley lifted its price target to $80, noting that Halozyme's 2025 earnings per share guidance has risen by 20 percent since January. The analyst credits this strength to disciplined cost management and successful partnerships, which are driving higher long-term earnings expectations.

Leerink upgraded Halozyme to Market Perform from Underperform, citing improved transparency around sales exposures and detailed cost savings benefits of subcutaneous products compared with intravenous alternatives.

???? Bearish Takeaways

JPMorgan modestly raised its target to $65 from $63 but maintained a Neutral rating, signaling a more cautious stance. This reflects more tempered expectations on near-term upside and valuation concerns.

Leerink, despite its upgrade, maintains a neutral position (Market Perform) and flags ongoing risks regarding single-payer exposures and the competitive landscape. The firm is less concerned about Medicare Part B risks than initially feared.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives or begin writing your own Narrative!

Halozyme Therapeutics has raised its 2025 revenue guidance, now expecting total revenue between $1,300 to $1,375 million and royalty revenue between $850 to $880 million. This reflects growth from previous estimates and underscores the company's confidence in its expanding business.

The company announced that Chief Financial Officer Nicole LaBrosse will continue in her role until a successor is appointed or until March 30, 2026. An external search for her replacement has begun. LaBrosse intends to depart for a new professional opportunity after that date.

Between July and September 2025, Halozyme repurchased 725,514 shares for $38.88 million. This brings the total buyback to over 11.1 million shares, amounting to $592.37 million since February 2024. This reflects ongoing efforts to return value to shareholders.

The Fair Value Estimate has decreased slightly from $75.44 to $74.44, reflecting more modest growth assumptions in updated models.

The Discount Rate has edged down from 7.17% to 7.16%, indicating a minor shift in perceived risk or cost of capital.

The Revenue Growth Assumption has fallen significantly from 19.1% to 16.2%, pointing to more conservative expectations for medium-term sales expansion.

The Net Profit Margin Estimate has decreased from 54.65% to 53.67%, suggesting slight downward revisions in anticipated profitability.

The Future P/E Ratio has risen modestly from 8.01x to 8.22x, which signals a minor increase in expected future earnings multiples.

Narratives are a smarter, more dynamic way to invest. A Narrative combines your view of a company's story with financial forecasts and fair value estimates, making it easy to understand not just the numbers but the story behind them. On Simply Wall St's Community page, millions use Narratives to see how the latest news and forecasts could affect when to buy or sell. Narratives are always up to date as new events unfold, so your decisions stay informed and timely.

Read the full original Narrative on Halozyme Therapeutics to stay ahead on:

How Halozyme's partnerships and ENHANZE platform are driving robust, high-margin royalty growth as the world shifts to subcutaneous drug delivery.

The evolving risks, including patent litigation, regulatory changes, and rising competition, that could impact future earnings and market positioning.

The analyst consensus for fair value, growth rates, and profit margins, and how these shift with every new development or report.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include HALO.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com